BACKGROUND
The prevalence of chronic hidradenitis suppurativa (CHS) in the population is about 0.1%, the current economic burden in Russia at the beginning of 2023 is estimated to be 43.9 billion rubles per year for population (300 thousand rubles per 1 patient). Genetically engineered biological agents (GEBA) may be recommended for patients as the first-line therapy. The extension of the GEBA application has changed the appealability and feasibility of achieving positive treatment outcomes.
OBJECTIVE
To develop the proposals on inter-team routing and optimization of the pharmaceutical provision of patients with CHS (ICD-10 code L73.2).
MATERIAL AND METHODS
The study provides the data from clinical practice based on healthcare organizations of Saint-Petersburg, data extrapolation on the Russian Federation. The routing of patients with CHS in Saint-Petersburg was described. Appealability of patients with CHS to the appropriate specialists (surgeons, dermatovenereologists) was evaluated. The amount of additional financing required for effective treatment of patients with severe and moderate forms of the disease was calculated.
RESULTS
It is estimated that 146.4 thousand people are affected by CHS in the Russian Federation. Patients with moderate and severe forms of the disease seek surgeons and dermatovenereologists medical care. Almost 87% of patients with moderate and severe forms of CHS receive medical care from a surgeon, which leads to more frequent recurrences and repeated surgical interventions (symptomatic therapy). One in seven to eight patients with moderate and severe forms of CHS receive medical care from a dermatovenereologist, which potentially provides them with GEBA (pathogenetic therapy).
CONCLUSION
Inter-team routing of patients is not organized. The proportion of severe forms of CHS, in which the prescription of GEBA is indicated, accounts for 0.5% (733 people in the RF), the amount of additional financing — 0.74 billion rubles. It is necessary to develop and approve the guidelines for the management of patients with CHS, regulating the inter-team interaction of specialists and optimizing the routing of patients.
